Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Soleno Therapeutics (SLNO) Stock Price & Analysis
635 Followers
SLNO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.69 - $53.82
Previous Close$40.91
Volume384.14K
Average Volume (3M)522.59K
Market Cap
$1.49B
Enterprise Value$1.34B
Total Cash (Recent Filing)$149.63M
Total Debt (Recent Filing)$347.00K
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 07, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding33,411,329
10 Day Avg. Volume536,577
30 Day Avg. Volume522,590
Standard Deviation0.70
R-Squared0.01
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)10.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-36.05
Forecast
1Y Price Target
$70.75Price Target Upside72.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Soleno Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Approval PotentialAnalyst recommends attention to SLNO's promising drug, DCCR, showing strong potential for approval in treating Prader-Willi syndrome, a condition with critical unmet medical needs.
Market OpportunitySLNO's focus on Prader-Willi syndrome, a market with no current approved treatments, could lead to significant pricing power and revenue opportunities upon drug approval.
Regulatory MilestonesPositive interactions with the FDA and robust clinical data position SLNO favorably for a successful New Drug Application submission, bolstering investor confidence.
Bears Say
Clinical Trial ResultsDCCR's failure to meet the primary endpoint in a pivotal Phase 3 trial could cast doubt on its efficacy, potentially affecting investor confidence.
Drug EfficacyDespite showing some positive metrics, DCCR's mixed clinical trial results could lead to skepticism about its market potential and affect stock performance.
Regulatory RisksClinical and regulatory risks for DCCR may pose a challenge to its approval process, potentially impacting the stock negatively.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $3.69 and its highest was $53.82 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Currently, no data Available
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 32 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on May 10, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.223.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is -$0.59.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 36,411,327 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went down -5.563%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Among the largest hedge funds holding Soleno Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Soleno Therapeutics Inc’s shares valued at 132M.
---
Soleno Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.75 (72.94% Upside)
$70.75 (72.94% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 63%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 130.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
881.05%
12-Months-Change
Fundamentals
Return on Equity
-71.26%
Trailing 12-Months
Asset Growth
764.28%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
---
SLNO Stock 12 Month Forecast
Average Price Target
$70.75
▲(72.94% Upside)
Technical Analysis
Abeona Therapeutics
―
Assertio Therapeutics
―
Gritstone Oncology
―
Kala Pharmaceuticals
―
Best Analysts Covering SLNO
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
+161.55%
assigned a buy rating 2 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of +161.55% per trade.
---